| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| ln Vitro |
FASN/SCD-IN-1 (Compound A2) (100-200 μM, 20-30 min) showed scavenging activity against DPPH and O2•–, with scavenging rates of 92.9% and 82.9%, respectively, and IC50 values of 33.4 and 28.1 μM, respectively. In the lipid peroxidation inhibition capacity (LPIC) assay, LPIC showed an inhibition rate of 67.0% and an IC50 of 41.7 μM[1]. FASN/SCD-IN-1 (10-40 μM, 24 hours) can reduce triglyceride (TG) levels and inhibit lipid accumulation in LO2 cells and mouse primary hepatocytes stimulated by Palmitic acid/Oleic acid (PO). It can also reduce the transcription levels of fatty acid synthase (FASN) and stearoyl-CoA desaturase (SCD) in PO-stimulated LO2 cells and reduce the expression of ACACA (encoding acetyl-CoA carboxylase) and FASN in PO-stimulated mouse primary hepatocytes [1]. FASN/SCD-IN-1 (1-10 μM, 24 hours) can reduce the levels of excess ROS and IL-6 and TNF-α mRNA in LO2 cells and mouse primary hepatocytes stimulated by Carbon tetrachloride (CCl4) [1]. FASN/SCD-IN-1 (10-40 μM, 48 hours) can inhibit the levels of collagen I and fibronectin (FN) in TGF-β stimulated LX2 cells [1].
|
|---|---|
| ln Vivo |
FASN/SCD-IN-1 (Compound A2) (100 mg/kg, gavage, once daily for 7 days) can protect against acute liver injury in a CCl4-induced acute liver injury model by restoring liver function, reducing electrolyte damage and repairing oxidative stress, thereby alleviating liver function damage [1]. FASN/SCD-IN-1 (150 mg/kg, injury, once daily for 4 weeks) can reduce steatosis and enhance oxidative, neural responses and liver fibrosis in HFD + CCl4-induced MASH mice, thus significantly improving the progression of MASH mice [1].
|
| Cell Assay |
Western Blot AnalysisTGF-β-stimulated LX2 cells
Cell Types: TGF-β-stimulated LX2 cells Tested Concentrations: 10 μM, 20 μM, 40 μM Incubation Duration: 48 h Experimental Results: Suppressed collagen I and FN levels. |
| Animal Protocol |
Animal/Disease Models: CCl4 (1 mg/kg, i.p.)-induced acute liver injury SD rat (male, 6 weeks) model[1]
Doses: 100 mg/kg Route of Administration: i.g. once a day, 7 days Experimental Results: Alleviated typical features of fatty liver disease, such as partial yellowing, darkening of the liver margins, white fat granules, and a rough surface. Reduced the hepatopancreatic somatic index (HSI) and liver-to-body weight ratio. Reduced serum AST, ALT, and LDH levels. Reduced liver vacuoles, acute fat deposition, elevation of the MDA level and and restored SOD activity. Animal/Disease Models: HFD + CCl4 (0.2 mg/kg, i.p., once a week)-induced MASH C57BL/6 mice (male, 6 weeks) model[1] Doses: 150 mg/kg Route of Administration: p.o., once a day, 4 weeks Experimental Results: Protected body weight and counteracts CCl4 toxicity. Reduced hepatopancreatic somatic index (HSI) and alleviates liver swelling. Alleviated liver damage and reverses CCl4-induced liver enlargement, pale color, and mottled texture. Reduced serum AST and ALT levels. Improved liver structural distortion and reverses CCl4-induced hepatocellular ballooning, inflammation, and steatosis. Ameliorated the dyslipidemia, reduced the elevated serum TG, cholesterol (CHO), and low-density lipoprotein cholesterol (LDL-c) levels and increased the lowered high-density lipoprotein cholesterol (HDL-c) levels. Reduced the hepatic TG and CHO levels. Restored the decreased liver GSH level and decrease the elevated MDA level, restore the decreased levels of both SOD and GSH-Px. Reduced IL-6 and TNF-α levels, reduced collagen deposition, levels of α-SMA and collagen I in the liver tissue. |
| References |
| Molecular Formula |
C25H22O9S
|
|---|---|
| Molecular Weight |
498.50
|
| CAS # |
3063509-61-2
|
| Appearance |
Typically exists as solids at room temperature
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0060 mL | 10.0301 mL | 20.0602 mL | |
| 5 mM | 0.4012 mL | 2.0060 mL | 4.0120 mL | |
| 10 mM | 0.2006 mL | 1.0030 mL | 2.0060 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
